About Suppression of tumorigenicity 18 protein
Suppression of tumorigenicity 18 protein (ST18) is a protein
from Homo sapiens identified by UniProt accession
O60284, 1047 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Suppression of tumorigenicity 18 protein |
|---|
| UniProt accession | O60284 |
|---|
| Gene | ST18 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1047 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (64)
Diseases linked to this target (Open Targets).
- chronotype measurement · score 0.41
- body height · score 0.39
- refractive error · score 0.35
- age at first sexual intercourse measurement · score 0.30
- IGF-1 measurement · score 0.29
- visual perception measurement · score 0.29
- age at onset · score 0.28
- Myopia · score 0.28
- Abnormality of refraction · score 0.28
- motion sickness · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60284-F1 | alphafold | PREDICTED | 54.32 | — |
Amino-acid sequence (1047 residues)
MDAEAEDKTL RTRSKGTEVP MDSLIQELSV AYDCSMAKKR TAEDQALGVP VNKRKSLLMK PRHYSPKADC QEDRSDRTED DGPLETHGHS TAEEIMIKPM DESLLSTAQE NSSRKEDRYS CYQELMVKSL MHLGKFEKNV SVQTVSENLN DSGIQSLKAE SDEADECFLI HSDDGRDKID DSQPPFCSSD DNESNSESAE NGWDSGSNFS EETKPPRVPK YVLTDHKKDL LEVPEIKTEG DKFIPCENRC DSETERKDPQ NALAEPLDGN AQPSFPDVEE EDSESLAVMT EEGSDLEKAK GNLSLLEQAI ALQAERGCVF HNTYKELDRF LLEHLAGERR QTKVIDMGGR QIFNNKHSPR PEKRETKCPI PGCDGTGHVT GLYPHHRSLS GCPHKVRVPL EILAMHENVL KCPTPGCTGR GHVNSNRNTH RSLSGCPIAA AEKLAMSQDK NQLDSPQTGQ CPDQAHRTSL VKQIEFNFPS QAITSPRATV SKEQEKFGKV PFDYASFDAQ VFGKRPLIQT VQGRKTPPFP ESKHFPNPVK FPNRLPSAGA HTQSPGRASS YSYGQCSEDT HIAAAAAILN LSTRCREATD ILSNKPQSLH AKGAEIEVDE NGTLDLSMKK NRILDKSAPL TSSNTSIPTP SSSPFKTSSI LVNAAFYQAL CDQEGWDTPI NYSKTHGKTE EEKEKDPVSS LENLEEKKFP GEASIPSPKP KLHARDLKKE LITCPTPGCD GSGHVTGNYA SHRSVSGCPL ADKTLKSLMA ANSQELKCPT PGCDGSGHVT GNYASHRSLS GCPRARKGGV KMTPTKEEKE DPELKCPVIG CDGQGHISGK YTSHRTASGC PLAAKRQKEN PLNGASLSWK LNKQELPHCP LPGCNGLGHV NNVFVTHRSL SGCPLNAQVI KKGKVSEELM TIKLKATGGI ESDEEIRHLD EEIKELNESN LKIEADMMKL QTQITSMESN LKTIEEENKL IEQNNESLLK ELAGLSQALI SSLADIQLPQ MGPISEQNFE AYVNTLTDMY SNLERDYSPE CKALLESIKQ AVKGIHV
Explore Suppression of tumorigenicity 18 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets